华仁药业9月30日获融资买入440.26万元，融资余额2.49亿元

Group 1: Stock Performance and Financing - On September 30, Huaren Pharmaceutical's stock increased by 0.62%, with a trading volume of 42.32 million yuan [1] - The financing buy-in amount for Huaren Pharmaceutical on the same day was 4.40 million yuan, while the financing repayment was 5.92 million yuan, resulting in a net financing buy of -1.52 million yuan [1] - As of September 30, the total margin balance for Huaren Pharmaceutical was 249 million yuan, accounting for 6.48% of its market capitalization, indicating a high level compared to the past year [1] Group 2: Business Overview - Huaren Pharmaceutical, established on May 20, 1998, and listed on August 25, 2010, is located in Qingdao, Shandong Province [1] - The company's main business includes large-volume intravenous solutions, peritoneal dialysis solutions, respiratory medications, narcotic medications, raw materials, medical packaging, medical devices, and health products [1] - The revenue composition of Huaren Pharmaceutical is as follows: basic intravenous solutions 40.63%, peritoneal dialysis solutions 34.90%, therapeutic preparations 14.92%, medical devices 8.14%, and others 1.41% [1] Group 3: Shareholder Information and Financial Performance - As of September 20, Huaren Pharmaceutical had 40,500 shareholders, a decrease of 1.46% from the previous period, with an average of 29,156 circulating shares per shareholder, an increase of 1.48% [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 4: Dividend Information - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3]